Mechanism of Action of Mavacamten
Introduction Mavacamten is an oral cardiac myosin inhibitor marketed under the brand name Camzyos. It is used for the treatment of adults with symptomatic New York Heart Association class II–III obstructive hypertrophic cardiomyopathy, also called obstructive HCM or oHCM, to improve functional capacity and symptoms. Current prescribing information describes Camzyos as a cardiac myosin inhibitor … Read more